IMMURON LTD (IMC) - Travelan's Record-Breaking Success Puts Immuron on the Global Health Map

Send us a textSteve Lydeamore, CEO of Immuron Limited, takes us behind the scenes of one of Australia's most innovative biopharmaceutical companies. What makes this Melbourne-based biotech unique is their dual focus—a thriving commercial product alongside a promising technology platform targeting infectious diseases.The spotlight falls on Travelan, Immuron's preventative treatment for traveller's diarrhoea that has experienced phenomenal growth. After sales plummeted to near-zero during the pandemic, the company has ssen a remarkable turnaround from $145,000 to over $5.3 million in less than a year. This success story involved strengthening pharmacy distribution networks across Australia and Canada while leveraging Amazon as their primary channel in the US market. As international travel rebounds, particularly to high-risk regions like Bali and Vietnam, Travelan's unique preventative approach—"nobody wants to get it"—positions it perfectly for continued growth.

There are no comments yet.

Please log in to write the first comment.